Cargando…
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
Malignant mesothelioma is a relatively rare malignancy arising in the body’s serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, poor prognosis and resistance to treatment. The development of various immunothe...
Autores principales: | Klampatsa, Astero, Albelda, Steven M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480947/ https://www.ncbi.nlm.nih.gov/pubmed/32914147 http://dx.doi.org/10.33696/immunology.2.042 |
Ejemplares similares
-
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017) -
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model
por: Klampatsa, Astero, et al.
Publicado: (2020) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
por: Hawkins, Elizabeth R, et al.
Publicado: (2021) -
Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
por: Bughda, Reyisa, et al.
Publicado: (2021) -
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)